Literature DB >> 19396863

A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect.

Luca Agnelli1, Laura Mosca, Sonia Fabris, Marta Lionetti, Adrian Andronache, Ivo Kwee, Katia Todoerti, Donata Verdelli, Cristina Battaglia, Francesco Bertoni, Giorgio Lambertenghi Deliliers, Antonino Neri.   

Abstract

Multiple myeloma (MM) is characterized by marked genomic heterogeneity. Beyond structural rearrangements, a relevant role in its biology is represented by allelic imbalances leading to significant variations in ploidy status. To elucidate better the genomic complexity of MM, we analyzed a panel of 45 patients using combined FISH and microarray approaches. We firstly generated genome-wide profiles of 41 MMs and four plasma cell leukemias, using a self-developed procedure to infer exact local copy numbers (CNs) for each sample. Our analysis allowed the identification of a significant fraction of patients showing near-tetraploidy. Furthermore, a conventional hierarchical clustering analysis showed that near-tetraploidy, 1q gain, hyperdiploidy, and recursive deletions at 1p and chromosomes 13, 14, and 22 were the main aberrations driving samples grouping. Moreover, mapping information was integrated with gene expression profiles of the tumor samples. A multiclass analysis of transcriptional profiles characterizing the different clusters showed marked gene-dosage effects, particularly concerning 1q transcripts; this finding was also confirmed by a nonparametric analysis between normalized gene expression levels and local CN variations (1027 highly-significant correlated genes). Finally, we identified several loci in which gene expression correlated with the occurrence of loss of heterozygosity. Our results provide insights into the composite network linking genome structure and transcriptional features in MM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19396863     DOI: 10.1002/gcc.20668

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  57 in total

Review 1.  The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Authors:  Sarah K Johnson; Christoph J Heuck; Anthony P Albino; Pingping Qu; Qing Zhang; Bart Barlogie; John D Shaughnessy
Journal:  Int J Hematol       Date:  2011-10-15       Impact factor: 2.490

2.  Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.

Authors:  Gang An; Yan Xu; Lihui Shi; Zhong Shizhen; Shuhui Deng; Zhenqing Xie; Weiwei Sui; Fenghuang Zhan; Lugui Qiu
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

3.  Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.

Authors:  Morihiko Sagawa; Hiroto Ohguchi; Takeshi Harada; Mehmet K Samur; Yu-Tzu Tai; Nikhil C Munshi; Masahiro Kizaki; Teru Hideshima; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2017-04-25       Impact factor: 12.531

4.  FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer.

Authors:  Geng Zhang; Peijun He; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Harris G Yfantis; Dong H Lee; Nader Hanna; H Richard Alexander; S Perwez Hussain
Journal:  Cancer Res       Date:  2013-06-25       Impact factor: 12.701

5.  The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.

Authors:  F Fan; M H Bashari; E Morelli; G Tonon; S Malvestiti; S Vallet; M Jarahian; A Seckinger; D Hose; L Bakiri; C Sun; Y Hu; C R Ball; H Glimm; M Sattler; H Goldschmidt; E F Wagner; P Tassone; D Jaeger; K Podar
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

6.  Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Hiroshi Handa; Yoshiko Sasaki; Hikaru Hattori; Lobna Alkebsi; Tetsuhiro Kasamatsu; Takayuki Saitoh; Takeki Mitsui; Akihiko Yokohama; Norifumi Tsukamoto; Morio Matsumoto; Hirokazu Murakami
Journal:  Oncol Lett       Date:  2017-07-26       Impact factor: 2.967

7.  C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma.

Authors:  Sai-Qun Luo; De-Hui Xiong; Jiang Li; Guangdi Li; Yali Wang; Jia-Ming Zhang; Xiu-Fen Bu; Wei-Xin Hu; Jingping Hu
Journal:  Oncogene       Date:  2020-02-27       Impact factor: 9.867

8.  IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal.

Authors:  Christian B Gocke; Ross McMillan; Qiuju Wang; Asma Begum; Vesselin R Penchev; Syed A Ali; Ivan Borrello; Carol Ann Huff; William Matsui
Journal:  Mol Cancer Ther       Date:  2016-08-29       Impact factor: 6.261

Review 9.  WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies.

Authors:  C Marcelo Aldaz; Brent W Ferguson; Martin C Abba
Journal:  Biochim Biophys Acta       Date:  2014-06-14

10.  CSNK1α1 mediates malignant plasma cell survival.

Authors:  Y Hu; W Song; D Cirstea; D Lu; N C Munshi; K C Anderson
Journal:  Leukemia       Date:  2014-06-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.